• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by SANUWAVE Health Inc.

    7/29/25 2:31:52 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care
    Get the next $SNWV alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    SANUWAVE Health Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    80303D305

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    80303D305


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,833.00
    7Sole Dispositive Power

    434,736.00
    8Shared Dispositive Power

    10,070.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    444,806.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.19 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    SANUWAVE Health Inc
    (b)Address of issuer's principal executive offices:

    3360 Martin Farm Rd, Suite 100, Suwanee, GA, 30024
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    80303D305
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    444806
    (b)Percent of class:

    5.19  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    6833

     (iii) Sole power to dispose or to direct the disposition of:

    434736

     (iv) Shared power to dispose or to direct the disposition of:

    10070

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:07/29/2025
    Get the next $SNWV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNWV

    DatePrice TargetRatingAnalyst
    9/3/2025$55.00Outperform
    Northland Capital
    7/29/2025$49.00Buy
    Roth Capital
    More analyst ratings

    $SNWV
    SEC Filings

    View All

    SEC Form S-8 filed by SANUWAVE Health Inc.

    S-8 - SANUWAVE Health, Inc. (0001417663) (Filer)

    8/22/25 4:32:39 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    SANUWAVE Health Inc. filed SEC Form 8-K: Other Events

    8-K - SANUWAVE Health, Inc. (0001417663) (Filer)

    8/21/25 4:40:01 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    SANUWAVE Health Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - SANUWAVE Health, Inc. (0001417663) (Filer)

    8/20/25 4:49:03 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    $SNWV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sanuwave Announces Q2 FY2025 Financial Results

    Q2 2025 revenues were $10.2 million, up 42% from $7.2 million in Q2 2024. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 gross margin was 78.3%, versus 73.2% in Q2 2024. GAAP Operating Income was $1.9 million for Q2 2025 versus $2.0 million in Q2 2024. Q2 2025 included equity compensation costs of $1.1 million versus $0 in Q2 2024. Company provides guidance for revenues of $12-$12.7 million for Q3 2025. EDEN PRAIRIE, Minn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three mon

    8/8/25 6:00:00 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Sanuwave Will Host a Conference Call on August 8, 2025 at 8:30 AM (ET) to Present Q2 2025 Financial Results

    EDEN PRAIRIE, Minn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, August 8, 2025, at 8:30 AM (ET) to present its Q2 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information  Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 Conference ID: SANUWAVE OR click the link for instant telephone access to the event: https://viavid.webcasts.com/starthere.jsp?ei=1723341&tp_key=b9f972bf82Materials for the conference call will be included

    8/4/25 5:00:00 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Sanuwave Health to Present at Canaccord Genuity Growth Conference

    EDEN PRAIRIE, Minn., July 22, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (NASDAQ:SNWV), a leading provider of next-generation, FDA-approved wound care products , today announced, that Morgan Frank, Chief Executive Officer, will present at the 45th Annual Canaccord Genuity Growth Conference, being held August 12–13, 2025, at the InterContinental Hotel in Boston, Massachusetts. Sanuwave's group presentation is scheduled for Wednesday, August 13, from 9:30 to 9:55 a.m. ET. In addition to the presentation, Mr. Frank will be available for one-on-one meetings with investors throughout the conference, which can be scheduled through the Canaccord Genuity conference portal. For additional inf

    7/22/25 4:05:00 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    $SNWV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Opaleye Management Inc. bought $203,875 worth of shares (7,998 units at $25.49) (SEC Form 4)

    4 - SANUWAVE Health, Inc. (0001417663) (Issuer)

    4/30/25 7:06:51 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    $SNWV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Tyler James

    4 - SANUWAVE Health, Inc. (0001417663) (Issuer)

    7/2/25 7:33:12 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Blizard Jeffrey

    4 - SANUWAVE Health, Inc. (0001417663) (Issuer)

    7/2/25 7:29:29 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Bazar Gregory Matthew

    4 - SANUWAVE Health, Inc. (0001417663) (Issuer)

    7/2/25 7:28:14 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    $SNWV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Northland Capital initiated coverage on SANUWAVE Health with a new price target

    Northland Capital initiated coverage of SANUWAVE Health with a rating of Outperform and set a new price target of $55.00

    9/3/25 9:10:05 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Roth Capital initiated coverage on SANUWAVE Health with a new price target

    Roth Capital initiated coverage of SANUWAVE Health with a rating of Buy and set a new price target of $49.00

    7/29/25 7:40:14 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    $SNWV
    Leadership Updates

    Live Leadership Updates

    View All

    Sanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial Operations

    EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the hiring of Dustin Libby as its EVP of commercial operations. Libby brings 20 years of medical device experience focused on commercial growth, sales operations, and launch execution. His career includes leadership roles at Abiomed where, as director of commercial operations, he helped scale a $15M surgical business to over $500M in revenue. Other roles include experience at Smith & Nephew, Arthrex, and Hill-ROM, where he directed sales enablement, operational strat

    6/3/25 7:30:00 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Sanuwave Health Appoints Greg Bazar to Board of Directors

    EDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the addition of Greg Bazar to its Board of Directors. Bazar brings decades of leadership experience in engineering, technology, and cybersecurity to Sanuwave's Board of Directors. He currently serves as Chairman of the Board at Simpatico Systems, a company he founded to deliver advanced IT and cybersecurity solutions. Previously, he was the first employee at intelligent connectivity provider 3D-P, where he played a pivotal role in the company's growth and strategic direction,

    5/28/25 4:05:00 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    $SNWV
    Financials

    Live finance-specific insights

    View All

    Sanuwave Announces Q2 FY2025 Financial Results

    Q2 2025 revenues were $10.2 million, up 42% from $7.2 million in Q2 2024. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 gross margin was 78.3%, versus 73.2% in Q2 2024. GAAP Operating Income was $1.9 million for Q2 2025 versus $2.0 million in Q2 2024. Q2 2025 included equity compensation costs of $1.1 million versus $0 in Q2 2024. Company provides guidance for revenues of $12-$12.7 million for Q3 2025. EDEN PRAIRIE, Minn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three mon

    8/8/25 6:00:00 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Sanuwave Will Host a Conference Call on August 8, 2025 at 8:30 AM (ET) to Present Q2 2025 Financial Results

    EDEN PRAIRIE, Minn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, August 8, 2025, at 8:30 AM (ET) to present its Q2 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information  Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 Conference ID: SANUWAVE OR click the link for instant telephone access to the event: https://viavid.webcasts.com/starthere.jsp?ei=1723341&tp_key=b9f972bf82Materials for the conference call will be included

    8/4/25 5:00:00 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Sanuwave Announces Q1 FY2025 Financial Results

    Q1 2025 revenues were $9.3 million, up 61% from $5.8 million in Q1 2024. This represents the highest Q1 quarterly revenues in Company history. Q1 2025 gross margin was 79.0%, versus 72.6% in Q1 2024. GAAP Operating Income was $1.0 million for Q1 2025, an increase of $2.0 million from Q1 2024. Company provides guidance for revenue growth of 40-50% for Q2 2025 as compared to Q2 2024 EDEN PRAIRIE, Minn., May 09, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three months ended March 31, 2025. Q1 2025 ended March 31, 202

    5/9/25 6:00:00 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care